Telix Q2 Revenue Hits $247M, Raises FY Outlook to Over $1B
TLX sits 67% above its 52-week low of $6.28.
Summary
Telix delivered Q2 revenue of $247M, a 7% sequential increase and 21% year-over-year, driven by its Precision Medicine segment. The company now expects full-year revenue to exceed $1B, tracking toward the upper end of its $950M–$970M guidance plus $40M from Regeneron. The FDA aligned on advancing the ProstACT Phase 3 trial of TLX591-Tx to Part 2 in the U.S., a key regulatory milestone. A strategic collaboration with Regeneron to co-develop next-generation radiopharmaceuticals adds a new growth vector. R&D spending guidance was raised to $230M–$270M, reflecting accelerated investment in the pipeline. This follows the recent opening of a Melbourne manufacturing facility and completion of enrollment in a Japanese Phase 3 study, underscoring commercial and clinical momentum.
At the time of this announcement, TLX was trading at $10.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $6.28 to $16.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.